Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma

Dogan, Bercem; Arduc, Ayse; Tuna, Mazhar; Berker, Dilek; Demirci, NİLGÜN; Demirtas, Semra; Cicekcioglu, Hulya; Guler, Serdar

doi:10.2174/1871530316666160229120142

Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma

Atıf İçin Kopyala

Dogan B. A., Arduc A., Tuna M. M., Berker D., Demirci N., Demirtas S., ...Daha Fazla

ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, cilt.16, sa.1, ss.47-55, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 1
Basım Tarihi: 2016
Doi Numarası: 10.2174/1871530316666160229120142
Dergi Adı: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.47-55
Gazi Üniversitesi Adresli: Evet

Özet

Aim: Cabergoline is related to an elevated risk of fibrotic adverse reactions including cardiac valvular and pleuropulmonary fibrosis. We investigated pulmonary and cardiac valve fibrosis and immunological markers before and after 3 and 12 months of treatment with cabergoline in women with prolactinoma.